H.C. Wainwright Reiterates Buy Rating on Oculis Holding AG (OCS)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $39.00 price target on Oculis Holding AG (NASDAQ: OCS).

The analyst commented: "New biomarker findings complement previously reported visual and retinal benefits from privosegtor. Yesterday, Oculis reported new biomarker analyses from the Phase 2 ACUITY trial of privosegtor in patients with acute optic neuritis (ON). Post-onset increases in plasma neurofilament light chain (NfL), a marker of neuroaxonal injury, and glial fibrillary acidic protein (GFAP), a marker of reactive astrocytic activation, were lower with privosegtor than placebo, particularly at early timepoints following disease onset. These findings complement the previously reported 18-letter benefit in low-contrast visual acuity (LCVA) at Month 3 vs. steroids alone, together with preservation of retinal structure. In our view, the complementary functional, structural and blood biomarker findings strengthen the biological rationale for privosegtor’s neuroprotective potential as Oculis advances its PIONEER registrational program in ON. The company is also planning an Investigational New Drug (IND) submission for acute multiple sclerosis (MS) relapses following constructive FDA pre-IND feedback. We reiterate our Buy rating and $39 price target."

For an analyst ratings summary and ratings history on Oculis Holding AG click here. For more ratings news on Oculis Holding AG click here.

Shares of Oculis Holding AG closed at $8.09 yesterday.

You May Also Be Interested In

• Shopify (SHOP) PT Lowered to $180 at DA Davidson
• Popular stocks with increasing option volume: INTC MU ORCL IREN RIOT MRVL HOOD NFLX CRWV WULF
• Vertex (VRTX) PT Raised to $619 at Cantor Fitzgerald